# Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

> **NCT06031194** · — · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Central Nervous System Lymphoma
- Diffuse Large B-Cell Lymphoma

## Interventions

- **OTHER:** Non-Interventional Study

## Key facts

- **NCT ID:** NCT06031194
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-10
- **Primary completion:** 2025-11-05
- **Final completion:** 2025-12-23
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06031194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06031194, "Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06031194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*